share_log

B. Riley Securities Downgrades Bicycle Therapeutics to Neutral, Lowers Price Target to $28

Benzinga ·  Aug 7 17:55  · Ratings

B. Riley Securities analyst Kalpit Patel downgrades Bicycle Therapeutics (NASDAQ:BCYC) from Buy to Neutral and lowers the price target from $33 to $28.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment